Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.

Sabin Göktas AydinYasin KutluHarun MugluAhmet AydinOzgur AcikgozJamshid HamdardEbru KarciAhmet BiliciOmer Fatih OlmezOzcan Yildiz

Published in: Cancer chemotherapy and pharmacology (2023)

mGPS and PSA doubling time significantly impacted survival, and mGPS significantly predicted the treatment response in mCRPC, which may lead to further prospective studies.

Keyphrases

prostate cancer
squamous cell carcinoma
small cell lung cancer
radical prostatectomy